Skip to main content
SpringerLink
Log in

Successful treatment of relapsed/refractory transformed aggressive B-cell lymphoma with polatuzumab vedotin combined with bendamustine and rituximab followed by non-myeloablative related HLA-haploidentical stem cell transplantation

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Sarkozy C, Maurer MJ, Link BK et al (2019) Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol 37:144–152

    Article  CAS  PubMed  Google Scholar 

  2. Lin P, Mansoor A, Bueso-Ramos C et al (2003) Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenstőm macroglobulinemia. Clinicopathologic features of 12 cases. Am J Clin Pathol 120:246–253

    Article  PubMed  Google Scholar 

  3. Sehn LH, Herrera AF, Flowers CR et al (2020) Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol: Off J Am Soc Clin Oncol 38:155–165

    Article  CAS  Google Scholar 

  4. Terui Y, Rai S, Izutu K et al (2021) A phase 2 study of polatuzumab vedtin+bendamustine+rituximab in relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci 112:2845–2854

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Liebers N, Duell J, Fitzgerald D et al (2021) Polatuzumab vedtin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphoma. Blood Adv 13:2707–2716

    Article  Google Scholar 

  6. Gerhardt K, Jentzsch M, Georgi T et al (2021) Salvage therapy with polatuzumab vedotin, bendamustine, and rituximab prior to allogeneic hematopoietic transplantation in patients with aggressive lymphomas relapsing after therapy with chimeric antigen receptor T-cell-Report on two cases. Front Oncol 11:737645

    Article  PubMed  PubMed Central  Google Scholar 

  7. Sugita J, Kamimura T, Ishikaw T et al (2021) Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant 56:596–604

    Article  CAS  PubMed  Google Scholar 

  8. Green TM, Young KH, Visco C et al (2012) Immunohistchemical double-hit score is a strong predictor of outcome in patiets with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3460–3467

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, St. Marianna University Yokohama City Seibu Hospital, 1197-1 Yasashi-Chou, Asahi-Ku, Yokohama, Kanagawa, 241-0811, Japan

    Shigeki Kosugi, Masatoshi Kanno & Yasuyuki Inoue

Authors
  1. Shigeki Kosugi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masatoshi Kanno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuyuki Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuyuki Inoue.

Ethics declarations

Ethics approval

This report was exempt from ethical approval according to the World Medical Association Declaration of Helsinki.

Consent to participate

A written informed consent to publish was obtained from the patient.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kosugi, S., Kanno, M. & Inoue, Y. Successful treatment of relapsed/refractory transformed aggressive B-cell lymphoma with polatuzumab vedotin combined with bendamustine and rituximab followed by non-myeloablative related HLA-haploidentical stem cell transplantation. Ann Hematol 102, 3277–3278 (2023). https://doi.org/10.1007/s00277-023-05366-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05366-4

Search

Navigation